ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival

被引:25
作者
Karakiewicz, Pierre I.
Trinh, Quoc-Dien
de la Taille, Alexandre
Abbou, Claude C.
Salomon, Laurent
Tostain, Jacques
Cindolo, Luca
Artibani, Walter
Ficarra, Vincenzo
Patard, Jean-Jacques
机构
[1] Univ Montreal, CHUM, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ H2X 3J4, Canada
[2] CHU Henri Mondor, Dept Urol, F-94010 Creteil, France
[3] CHU St Etienne, North Hosp, Dept Urol, St Etienne, France
[4] G Rummo Hosp, Dept Urol, Benevento, Italy
[5] Univ Verona, Dept Urol, I-37100 Verona, Italy
[6] Rennes Univ Hosp, Dept Urol, Rennes, France
关键词
renal cell carcinoma; prognosis; ECOG; symptoms; survival;
D O I
10.1016/j.ejca.2007.01.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: We tested and compared the improvement in prognostic ability related to the consideration of either ECOG performance status (ECOGPS) and/or symptom classification (S-CLASS) in renal cell carcinoma specific mortality (RCC-SM) predictions. Methods: Univariate and multivariate Cox regression analyses targeted RCC-SM in 2570 RCC patients treated with either partial or radical nephrectomy. The increment in predictive accuracy related to the addition of either ECOGPS, S-CLASS or both was quantified using Harrell's concordance index. Results: Follow-up ranged from 0.1 to 23 years (median 3.2) and 610 patients (23.7%) died of RCC. In multivariable analyses, ECOGPS and S-CLASS represented independent predictors of RCC-SM. The addition of ECOGPS to established RCC-SM predictors increased the predictive accuracy by 0.3% (p = 0.8) versus 0.6% (p = 0.5) for S-CLASS versus 0.6% (p = 0.5) for both. Conclusions: Neither ECOGPS nor S-CLASS improves the ability to predict RCC-SM. Therefore, these variables may be safely omitted when RCC-SM risk is quantified. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 27 条
[1]   Immunotherapy for renal cell carcinoma [J].
Bleumer, I ;
Oosterwijk, E ;
De Mulder, P ;
Mulders, PFA .
EUROPEAN UROLOGY, 2003, 44 (01) :65-75
[2]   Laparoscopic radical nephrectomy: Cancer control for renal cell carcinoma [J].
Chan, DY ;
Cadeddu, JA ;
Jarrett, TW ;
Marshall, FF ;
Kavoussi, LR .
JOURNAL OF UROLOGY, 2001, 166 (06) :2095-2099
[3]  
CHUN FK, 2006, EUR UROL
[4]   A preoperative clinical prognostic model for non-metastatic renal cell carcinoma [J].
Cindolo, L ;
de la Taille, A ;
Messina, G ;
Romis, L ;
Abbou, CC ;
Altieri, V ;
Rodriguez, A ;
Patard, JJ .
BJU INTERNATIONAL, 2003, 92 (09) :901-905
[5]  
ELSON PJ, 1988, CANCER RES, V48, P7310
[6]   Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer [J].
Flanigan, RC ;
Salmon, SE ;
Blumenstein, BA ;
Bearman, SI ;
Roy, V ;
McGrath, PC ;
Caton, JR ;
Munshi, N ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1655-1659
[7]   An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score [J].
Frank, I ;
Blute, ML ;
Cheville, JC ;
Lohse, CM ;
Weaver, AL ;
Zincke, H .
JOURNAL OF UROLOGY, 2002, 168 (06) :2395-2400
[8]   Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer [J].
Graefen, M ;
Ohori, M ;
Karakiewicz, PI ;
Cagiannos, I ;
Hammerer, PG ;
Haese, A ;
Erbersdobler, A ;
Henke, RP ;
Huland, H ;
Wheeler, TM ;
Slawin, K ;
Scardino, PT ;
Kattan, MW .
JOURNAL OF UROLOGY, 2004, 171 (01) :200-203
[9]  
*GREEN FLAMERICAN, 2002, AJCC CANC STAG MAN
[10]   Rising incidence of small renal masses: A need to reassess treatment effect [J].
Hollingsworth, John M. ;
Miller, David C. ;
Daignault, Stephanie ;
Hollenbeck, Brent K. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (18) :1331-1334